Last reviewed · How we verify
Cubicin
At a glance
| Generic name | Cubicin |
|---|---|
| Sponsor | Clinical Alliance for Research & Education - Infectious Diseases, LLC. |
| Target | Outer membrane porin protein OmpD |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Bacteremia caused by Staphylococcus aureus
- Complicated Skin and Skin Structure Enterococcus Faecalis Infection
- Complicated Skin and Skin Structure Staphylococcus Aureus Infection
- Complicated Skin and Skin Structure Streptococcus Agalactiae Infection
- Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
- Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection
- Right-sided Staphylococcus aureus endocarditis
- Secondary infection of erosion and ulcer caused by MRSA
- Secondary infection of surgical wounds caused by MRSA
- Secondary infection of trauma, and burn wounds caused by MRSA
- Sepsis caused by methicillin resistant Staphylococcus aureus
- Sepsis due to Staphylococcus aureus
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
- Fatigue
- Weakness
- Rigors
- Flushing
- Hypersensitivity
- Leukocytosis
- Thrombocytopenia
- Thrombocytosis
Serious adverse events
- Gram-negative infections (bloodstream infections)
- Cardiac arrest
- Atrial fibrillation
- Atrial flutter
- Fungemia
- Cholangitis
- Sternal osteomyelitis/mediastinitis
- Bowel infarction
- Line sepsis
- Urosepsis
Key clinical trials
- Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia (PHASE4)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Population Pharmacokinetics of Anti-infectives in Critically Ill Children
- In Vivo Antibiotics Removal During Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit
- Staphylococcus Aureus Network Adaptive Platform Trial (PHASE4)
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |